Sinopia Biosciences Awarded NHLBI Phase I SBIR

Sinopia Biosciences, a small biotechnology company in San Diego, received a second Phase I Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) branch of the National Institutes of Health (NIH). The award for approximately $220,000 will support the expansion and further development of Sinopia's bioinformatics and systems biology platform for transfusion medicine. This particular grant focuses on extending work on the platform for studying the metabolic consequences of the platelet storage legion.